Cena / účtovná hodnotae spoločnosti Hutchison China MediTech

Aká je hodnota metriky Cena / účtovná hodnotae spoločnosti Hutchison China MediTech?

Hodnota metriky Cena / účtovná hodnotae spoločnosti Hutchison China MediTech Ltd. je 3.26

Aká je definícia metriky Cena / účtovná hodnotae?



Cena / učtovná hodnota (Price to book ratio) ukazateľ vyjadruje pomer medzi hodnotou spoločnosti a book value spoločnosti, čo je hodnota čistých aktív.

The price to book ratio, or P/B ratio, is a financial ratio used to compare a company's current market price to its book value. It is also sometimes known as a market to book ratio or price to equity ratio. The calculation of a price to book ratio can be performed in two ways. It can be calculated as the company's market capitalization divided by the company's total book value from its balance sheet. It can also be calculated using per-share values and dividing a company's current share price by the book value per share (i.e. its book value divided by the number of outstanding shares).

The P/B ratio varies between industries. The industries that require more infrastructure capital (for each dollar of profit) will usually trade at P/B ratios much lower than, for example, consulting firms. P/B ratios are commonly used to compare banks, because most assets and liabilities of banks are constantly valued at market values. A higher P/B ratio implies that investors expect management to create more value from a given set of assets, all else equal (and/or that the market value of the firm's assets is significantly higher than their accounting value).

P/B ratios do not, however, directly provide any information on the ability of the firm to generate profits or cash for shareholders. This ratio also gives some idea of whether an investor is paying too much for what would be left if the company went bankrupt immediately. For companies in distress, the book value is usually calculated without the intangible assets that would have no resale value. In such cases, P/B should also be calculated on a "diluted" basis, because stock options may well vest on sale of the company or change of control or firing of management.

Cena / účtovná hodnotae spoločností v sektore Health Care sektor na LSE v porovnaní so spoločnosťou Hutchison China MediTech

Čomu sa venuje spoločnosť Hutchison China MediTech?

HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases worldwide. It operates in two segments, Oncology/Immunology and Other Ventures. It manufactures, distributes, markets, and sells prescription and over-the-counter pharmaceutical, and consumer health products. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and clear cell renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, an inhibitor for indolent non-Hodgkin's lymphoma (NHL), B-cell malignancies, and immune thrombocytopenic purpura; and HMPL-689 for indolent non-Hodgkin's, follicular, marginal zone, mantle cell, diffuse large B cell, chronic lymphocytic leukemia/small lymphocytic, and Hodgkin's lymphoma. The company develops HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-295 for solid tumors; and HMPL-813 and HMPL-309 EGFR inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics (Suzhou) Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Central, Hong Kong.

Firmy s metrikou cena / účtovná hodnotae podobnou spoločnosti Hutchison China MediTech



  • Hodnota metriky Cena / účtovná hodnotae spoločnosti European Metals je 3.26
  • Hodnota metriky Cena / účtovná hodnotae spoločnosti Smooth Rock Ventures je 3.26
  • Hodnota metriky Cena / účtovná hodnotae spoločnosti Siemens Gamesa Renewable SA je 3.26
  • Hodnota metriky Cena / účtovná hodnotae spoločnosti Ecc Ventures 3 Corp je 3.26
  • Hodnota metriky Cena / účtovná hodnotae spoločnosti Nitro Software je 3.26
  • Hodnota metriky Cena / účtovná hodnotae spoločnosti Kanchi Karpooram je 3.26
  • Hodnota metriky Cena / účtovná hodnotae spoločnosti Hutchison China MediTech je 3.26
  • Hodnota metriky Cena / účtovná hodnotae spoločnosti Core-Mark Hldg Co Inc je 3.26
  • Hodnota metriky Cena / účtovná hodnotae spoločnosti Cbiz Inc je 3.26
  • Hodnota metriky Cena / účtovná hodnotae spoločnosti eBay je 3.26
  • Hodnota metriky Cena / účtovná hodnotae spoločnosti Nomad Technologies je 3.26
  • Hodnota metriky Cena / účtovná hodnotae spoločnosti Mukand je 3.26
  • Hodnota metriky Cena / účtovná hodnotae spoločnosti Azarga Uranium je 3.26